Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PCSK9 inhibitors

- PMLiVE

England opens new NHS ‘front door’ to health innovators

An upgrade to existing ACC initiative

AstraZeneca AZ

Oncology drives AstraZeneca, Genzyme boosts Sanofi

Specialist drugs are growth engines in Q1

- PMLiVE

Amgen and UCB’s Evenity finally approved, but with label warnings

Drug unlikely to match Prolia's revenues

- PMLiVE

Alnylam swaps Sanofi for Regeneron as R&D partner

Novel alliance between two biotechs

- PMLiVE

Sanofi exits R&D pact with Alnylam on rare disease

Exit also frees up $700m equity investment

- PMLiVE

Novartis and Amgen come to blows over migraine partnership

Amgen seeks to terminate contract

- PMLiVE

Success for AZ, setback for Sanofi in type 1 diabetes

Forxiga approved as add-on to insulin

- PMLiVE

Amgen, Servier heart failure drug clears trial hurdle

Drug could be a blockbuster - if it hits key endpoints

- PMLiVE

Sanofi gets cardio outcomes claim for Praluent in EU

Data stronger than rival's, could spark a fight back

- PMLiVE

UK Biobank generates “largest open access resource of exome data”

Around 50,000 de-identifed genetic profiles available for research

- PMLiVE

Amgen, Servier start second phase 3 trial of heart failure hope

Treatment is one of few in underserved area

- PMLiVE

Sanofi extends growth spurt thanks to Genzyme, Dupixent

US approval of Cablivi adds to good news

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links